Company research
Alaunos Therapeutics, Inc.
CIK 1107421Updated Sep 24, 2026
SecurityTCRT · NASDAQ · equity
Name history
ZIOPHARM ONCOLOGY INC · through Jan 4, 2022EASYWEB INC · through Sep 19, 2005
TCRT price & chart
Loading TradingView…
NASDAQ:TCRT on TradingView ↗About the company
Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics. The Company’s obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B3 filing
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03
10-Q filing
4 filing
Show 5 more recent filings
S-8 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,966,000Source | 2,755,000Source | 8,263,000Source | 64,937,000Source |
| Property, Plant and Equipment, NetUSD | 91,000Source | 0Source | 2,000Source | 8,460,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,385,000Source | 1,091,000Source | 6,062,000Source | 39,058,000Source |
| Assets, CurrentUSD | 1,988,000Source | 2,755,000Source | 8,261,000Source | 53,799,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 600,000Source | 1,659,000Source | 2,198,000Source | 799,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 0Source | 2,136,000Source |
| Other Assets, NoncurrentUSD | — | — | 0Source | 500,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 813,000Source | 692,000Source | 1,956,000Source | 26,382,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 16,000Source | 240,000Source |
| Retained Earnings (Accumulated Deficit)USD | -924,622,000Source | -920,446,000Source | -915,767,000Source | -880,627,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,153,000Source | 2,063,000Source | 6,307,000Source | 38,555,000Source |
| Additional Paid in Capital, Common StockUSD | 926,773,000Source | 922,507,000Source | 922,058,000Source | 918,942,000Source |
| Liabilities and EquityUSD | 2,966,000Source | 2,755,000Source | 8,263,000Source | 64,937,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 813,000Source | 692,000Source | 1,956,000Source | 24,166,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 0Source | 0Source |
| Accounts Payable, CurrentUSD | 613,000Source | 516,000Source | 616,000Source | 1,389,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 28,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 200,000Source | 176,000Source | 1,340,000Source | 5,454,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 481,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 0Source | 16,765,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 796,000Source | 435,000Source | 2,800,000Source | 3,528,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 97,000Source | -100,000Source | -773,000Source | -25,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -2,869,000Source | -4,971,000Source | -30,142,000Source | -29,232,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -98,000Source | 0Source | 1,346,000Source | -193,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 98,000Source | 0Source | 197,000Source | 216,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 0Source | 45,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,261,000Source | 0Source | -18,138,000Source | 6,367,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 18,105,000Source | 8,333,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 294,000Source | -4,971,000Source | -46,934,000Source | -23,058,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,385,000Source | 1,091,000Source | 6,062,000Source | 52,996,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 2,063,000Source | 2,171,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | — | 0Source | 1,339,000Source | 981,000Source |
| DepreciationUSD | 7,000Source | 2,000Source | 2,315,000Source | 2,759,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | -7,000Source | -7,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | 0Source | 298,000Source | 133,000Source |
| General and Administrative ExpenseUSD | 2,867,000Source | 4,460,000Source | 12,219,000Source | 13,142,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -4,176,000Source | -4,679,000Source | -35,140,000Source | -37,730,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -4,282,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 49,000Source | 133,000Source | -873,000Source | -2,625,000Source |
| Operating ExpensesUSD | 4,230,000Source | 4,822,000Source | 34,272,000Source | 38,027,000Source |
| Other Nonoperating Income (Expense)USD | 80,000Source | 133,000Source | 1,048,000Source | 529,000Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 92,000Source | 14,724,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | 21,000Source |
| Restructuring CostsUSD | — | 0Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 5,000Source | 10,000Source | 5,000Source | 2,922,000Source |
| Operating Income (Loss)USD | -4,225,000Source | -4,812,000Source | -34,267,000Source | -35,105,000Source |
| Other Nonoperating Income (Expense)USD | 80,000Source | 133,000Source | 1,048,000Source | 529,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -4,176,000Source | -4,679,000Source | -35,140,000Source | -37,730,000Source |
| Earnings Per Share, BasicUSD per share | -2.2Source | -2.92Source | -2.2Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | -2.2Source | -2.92Source | -2.2Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,948,357Source | 1,601,252Source | 15,995,323Source | 217,130,311Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,948,357Source | 1,601,252Source | 15,995,323Source | 217,130,311Source |
| Interest Expense (non-operating)USD | — | 0Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 2,867,000Source | 4,460,000Source | 12,219,000Source | 13,142,000Source |
| Interest ExpenseUSD | — | — | 1,921,000Source | 3,154,000Source |
| Interest Expense, DebtUSD | — | — | 1,900,000Source | 3,200,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -4,282,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 49,000Source | 133,000Source | -873,000Source | -2,625,000Source |
| Operating ExpensesUSD | 4,230,000Source | 4,822,000Source | 34,272,000Source | 38,027,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 106,000Source | — | — | — |
| Research and Development ExpenseUSD | 1,363,000Source | 362,000Source | 16,279,000Source | 25,018,000Source |
| Restructuring CostsUSD | — | 0Source | — | — |
Offerings
Registration 333-291002
Filing attachments
tcrt-ex4_1.htm · 8-K · 2026-09-22
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ALAUNOS THERAPEUTICS, INC. Warrant Number: [●] Issue Date: [●] Warrant Shares: [●] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”), and until this Warrant is exerci…
Read attachment ↗tcrt-ex99_1.htm · 8-K · 2026-09-22
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for a…
Read attachment ↗tcrt-ex99_1.htm · 8-K · 2026-06-29
EX-99.1 2 tcrt-ex99_1.htm EX-99.1 EX-99.1 FOR IMMEDIATE RELEASE Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study • This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model • Liver-weight findings are directionally consistent with previously disclosed data on lower liver in…
Read attachment ↗tcrt-ex99_1.htm · 8-K · 2026-05-26
EX-99.1 2 tcrt-ex99_1.htm EX-99.1 EX-99.1 Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies • ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice • A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fl…
Read attachment ↗tcrt-ex99_1.htm · 8-K · 2026-05-18
EX-99.1 2 tcrt-ex99_1.htm EX-99.1 EX-99.1 FOR IMMEDIATE RELEASE Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosis FORT LAUDERDALE, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics…
Read attachment ↗